Clinical Study And Experimental Study On Treatment Of Tourette's Syndrome (TS) By Qiangzhisan

Objective: To evaluate the clinic efficacy of Qiangzhisan in patients with Tourette's Syndrome (TS),and to explore the mechanism.Methods:Clinical studies:According to the diagnostic criteria, 66 TS patients were randomly divided into two groups. The treatment group (n=33) received Yishenqiangzhi therapy, and the control group (n=33) received oral haloperidol therapy,observe children symptoms, signs and EEG. Experimental studies: Select randomly 10 cases respectively, normal children, the treatment group and control of children's venous blood. Using HPLC test before and after the treatment serum concentration of Glu,γ-GABA.Results: Clinical studies:The treatment group 15.15% clinical control of 5 cases, 51.52% clinical powerful of 17 cases,24.24% clinical batter of 8 cases,and total effective rate is 90.91%, the control group 9.09% clinical control of 3 cases, 45.45% clinical powerful of 15 cases,33.33% clinical better of 11 cases,and total effective rate is 81.87%, there are no differences in the total curative effect comparison (P>0.05). After treatment, the treatment group got improvement than the control group in EEG (P<0.05); The treatment group adverse reaction rate obviously lower than the control group(P<0.01). Experimental studies: After the treatment,the serum of Glu concentration drops, the density is no significant differences (P>0.05).γ-GABA concentration not detected.Conclusion:1.Qiangzhisan treatment Ts shenzhibuzu certificate is valid; 2.Qiangzhisan treatments Ts effective mechanism may be unclear of its adjustment amino acid neurotransmitter.